It Is my understanding that Opana is going to take the place of Oxycontin. Is this tru and why replace Oxycontin with something more addictive
10 Nov 2010
The manufacturer of the old style Oxycontin, Purdue Pharm, acquired Ethex Manufacturers to distribute the OC's for them. It's being marketed in generic form as Oxycodone ER in 80 mg & 40 mg only, but unfortunately only Walgreens is carrying this brand name. Let me warn you though, pretty much every pharmacy is very hesitant to give any information what so ever concerning Schedule II medications over the phone, unless they know you due to the rash of daytime robberies not too long ago looking for, you got it, Oxycontin!! There's one more company that distributes the 20 mg only, called Apotex. As far as I know once again, Walgreens only carries this. You must completely trust & believe me when I tell you, IT REALLY IS EXACTLY THE SAME MEDICATION. It's says OC on one side & 80 on the other, is the same exact color & same size.
It will begin to melt in your mouth, if for some reason you can't swallow it immediately, so that alone tells me they ARE NOT the OP's. The OP's gave me horrible stomach pains with worsened constipation. Worse of all (I'll swear on a mountain of Bibles, too!!) those darn things passed completely through my intestinal tract & on out completely whole, without dissolving at all. Now you tell me, how can a medication perform its duty if it can't break apart to let the chemicals do what they're suppose to do? Recently I read they've discovered yet another dangerous side effect from them. If you have a damaged liver, etc.,be careful because whatever they have used for the reformulation to make it abuse resistant, has the possibility of causing further or additional problems or damage.
I believe this is the longest response I've submitted since joining this valuable forum recently. This website has been so very helpful, supportive and been full of accurate knowledge on any question I've needed answers for. Thank you Drugs.com for being there for me.
I truly hope this give you the answers you seek & you're a little less stressed & the future looks a little bit more positive. Don't hesitate in letting me know if you need help with anything else...
26 Oct 2010
I copied this information for you. It is Purdue's Official Statement regarding oxycontin. Many patients are simply switching over to the Opana because of the problems they're having with this new reformulation of Oxycontin. As far as its' addicting qualities, many feel both (Opana and Oxy) are equally addictive. The new OP (all strengths) will be replacing the regular OC version by the end of 2010. Many people are having problems with this new medication. Here is Purdue's official statement and the reps you can contact with any concerns/complaints, or questions you may have.
(203) 588-8069 (office)
(203) 856-2121 (mobile)
(203) 856-7670 (office)
(203) 609-1291 (mobile)
April 5, 2010 - The U.S. Food and Drug Administration (FDA) approved Purdue Pharma L.P.'s New Drug Application for a reformulation of OxyContin® (oxycodone HCl controlled-release) Tablets.
The reformulation has met FDA criteria for bioequivalence to the original formulation, which means there is no significant difference in the rate and extent of absorption of the therapeutic ingredient.
While similar in appearance to the original formulation, the reformulated tablets have a different marking ("OP") than the currently marketed tablets (marking "OC") and the 60 mg and 80 mg tablets are slightly larger in size than the currently marketed tablets.
Purdue elected to reformulate OxyContin® to be bioequivalent to the original formulation and in an effort to make the tablet more difficult to manipulate for the purpose of intentional misuse and abuse, however, there is no evidence that the reformulation of OxyContin is less subject to misuse, abuse, diversion, overdose or addiction.
OxyContin® continues to be a CII controlled substance with all the attendant risks of Schedule II opioids, specifically that the drug has a high potential for abuse. Use, misuse, or abuse of the drug may lead to physical dependence or addiction (addiction is sometimes referred to as "psychological dependence"). In addition, alteration of the tablet in any manner poses significant risks of overdose and death. The Full Prescribing Information contains warnings about the potential for abuse, diversion, overdose and addiction, including a boxed warning (see below).
Indications and Usage
OxyContin® is a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
Limitations of Usage
OxyContin® is not intended for use on an as-needed basis.
As used here, "moderate" and "moderate to severe" pain do not include commonplace and ordinary aches and pains, pulled muscles, cramps, sprains, or similar discomfort.
OxyContin® is not indicated for the management of pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin® is indicated for postoperative use following the immediate post-operative period only if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.)
OxyContin® is not indicated for pre-emptive analgesia (preoperative administration for the management of postoperative pain).
OxyContin® is not indicated for rectal administration.
Important Safety Information
OxyContin® is contraindicated in patients who have significant respiratory depression, patients who have or are suspected of having paralytic ileus, patients who have acute or severe bronchial asthma, and patients who have known hypersensitivity to any of its components or the active ingredient, oxycodone.
Opioid analgesics have a narrow therapeutic index in certain patient populations, especially when combined with CNS depressant drugs, and should be reserved for cases where the benefits of opioid analgesia outweigh the known risks of respiratory depression, altered mental state, and postural hypotension. Use low initial doses of OxyContin® in patients who are not already opioid-tolerant, especially those who are receiving concurrent treatment with muscle relaxants, sedatives, or other CNS active medications.
Serious adverse reactions which may be associated with OxyContin® Tablet therapy in clinical use are respiratory depression, apnea, respiratory arrest, and circulatory depression, hypotension, or shock. The most common adverse reactions (>5%) include: constipation, nausea, somnolence, dizziness, vomiting, pruritus, headache, dry mouth, asthenia, and sweating.
Working with the FDA, Purdue has developed a Risk Evaluation and Mitigation Strategy (REMS) for OxyContin® Tablets. The OxyContin REMS includes a Medication Guide, Elements to Assure Safe Use, such as healthcare provider training and a timetable for submitting assessments of the REMS.
The Company expects to begin shipping all dosage strengths of the reformulated product (10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg) to distributors and pharmacies during the third quarter of 2010, at which time Purdue will cease shipping the original formulation.
"We will work with distributors and pharmacies for a smooth transition to the reformulation that will maintain product supply and protect patient access," said John H. Stewart, President and CEO of Purdue Pharma L.P.
- OxyContin Information for Consumers
- OxyContin Information for Healthcare Professionals (includes dosage details)
- Side Effects of OxyContin (detailed)
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Purdue won a lawsuit a couple of years ago stopping any companies from making a generic version of Oxycontin. They were going to sell what was left. ...
1 answer • 27 Jan 2010
suppose to be the generic form of it or is this what is replacing the ones that show OC on it. Is Purdue done making the ones that say OC on one side ...
1 answer • 30 Aug 2010
People should be able to get name brand that they've been getting regardless of any issues.I know for a fact the name brand last longer and are ...
1 answer • 11 Sep 2010
... being made by Purdue but being distributed by Ethex. The post was long, posted by "puff". It mentioned that Walgreens has them. I ...
1 answer • 25 Sep 2010